(PB)PK modellen van antikankergeneesmiddelen in kinderen met ALL, inclusief maturatie met behulp van longitudinale analyse.
All people living with HIV need life-long treatment with antiretroviral therapy (ART). However, ART coverage in children living with HIV continues to lag behind adults and many paediatric patients in sub-Saharan Africa still do not receive optimal paediatric treatment formulations or state-of-the-art drugs. Studies of efficacy and safety of these drugs in children have lagged behind, and the full range of appropriate formulations to treat younger children are yet to be developed for both first- and second-line treatments.
Opzetten van nieuwe bepalingsmethoden; onder meer disulfiram en koper als toepassing bij ewing sarcoma, asparaginase activiteit en eiwit, monoklonale antilichamen.